OTHER INFORMATION
+Added: (a) Entry into a Material Definitive Agreement
+Added: On May 6, 2024, we amended our facility lease agreement (the lease as amended, the “Amended Lease”) with BMR-Pacific Research Center LP to lease 60,575 rentable square feet of office and laboratory space located within the Newark, California facility the Company has occupied since 2017.
+Added: The term of the Amended Lease commences on July 1, 2024 (or such later date when tenant improvements in newly leased office space within the facility are substantially
+Added: The term of the Amended Lease is 65 months.
+Added: The initial monthly base rent under the Amended Lease is $3.53 per square foot.
+Added: Base rent will increase 3.5% annually.
+Added: The Amended Lease provides for an agreed-upon period of rent abatement.
+Added: We are responsible for our proportional share of operating expenses and tax obligations throughout the lease term.
+Added: No additional security deposit was required pursuant to the Amended Lease.
+Added: The foregoing description of the Amended Lease does not purport to be complete and is qualified in its entirety by reference to the Amended Lease, a copy of which will be filed as an exhibit to the Company’s quarterly report on Form 10-Q for the period ending June 30, 2024.
+Added: (c) Trading Plans
+Added: During the fiscal quarter ended March 31, 2024, no director or Section 16 officer adopted or terminated any Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement (in each case as defined in Item 408(a) of Regulation S-K.
EXHIBIT INDEX
3 unchanged sentences
Amended and Restated Bylaws
−Removed: Form of Pre-Funded Warrant
+Added: License and Collaboration Agreement by and between Protagonist Therapeutics, Inc.
+Added: and Takeda Pharmaceuticals USA, Inc.
+Added: dated January 31, 2024
Certification of Chief Executive Officer required by Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
14 unchanged sentences
PROTAGONIST THERAPEUTICS, INC.
−Removed: November 2, 2023
/s/ Dinesh V.
1 unchanged sentence
(Principal Executive Officer)
−Removed: November 2, 2023
Executive Vice President, Chief Financial Officer
1 unchanged sentence
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.